Matrigen Inc., Prizm deal

The companies merged to form Selective Genetics Inc. (San Diego, Calif.) in a stock deal valued at $30 million. Prizm shareholders own two-thirds of Selective, while Matrigen shareholders own the remaining third. The combined company employs 47 people and has $5.6 million in cash. The merger combines Matrigen's Gene Activated Matrix (GAM) technology with Prizm's Directin fibroblast growth factor (FGF) gene targeting technology. Selective plans to enter clinical trials in ovarian and pancreatic cancers by the end of the year with an adenoviral vector coated with fibroblast growth factor. The company also has GAM/FGF programs in bone and tissue repair and regeneration. ...